Tesla gains as Musk buys $1 billion in stock; closes well-off highs
Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (NASDAQ:CRMD), sold a total of 53,997 shares of common stock on September 9 and September 11, 2025, for approximately $711,817. The sales were executed at a weighted average price ranging from $13.08 to $13.51. According to InvestingPro data, CRMD has delivered an impressive 90.8% return over the past year, with analysts setting price targets between $17 and $23. The company’s current market capitalization stands at $982 million.
On September 9, Hurlburt sold 12,876 shares. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.61. On September 11, she sold 41,121 shares in multiple transactions at prices ranging from $12.98 to $13.17. InvestingPro analysis indicates the stock is currently undervalued, with the company maintaining a "GREAT" financial health score and holding more cash than debt on its balance sheet.
On the same dates, Hurlburt also exercised options to acquire a total of 53,997 shares of CorMedix common stock at a price of $1.45 per share, for a total value of $78,295. For deeper insights into CRMD’s valuation and 12+ additional ProTips, including detailed analyst forecasts and comprehensive financial metrics, visit InvestingPro.
In other recent news, CorMedix Inc . has completed a $150 million convertible notes offering, with the notes set to mature in 2030. This private placement was conducted under an exemption from registration, and the notes have an initial conversion rate of 74.2515 shares per $1,000 principal amount. In a significant acquisition move, CorMedix has agreed to purchase Melinta Therapeutics LLC for $300 million, comprising $260 million in cash and $40 million in equity. This acquisition will add seven drug products to CorMedix’s commercial portfolio. Additionally, CorMedix led a $29 million financing round for Talphera, Inc., securing an initial $17 million with the potential for an additional $12 million based on clinical study outcomes. CorMedix also made a strategic $5 million equity investment in Talphera, granting them exclusive negotiation rights to acquire the company after specific clinical results. Meanwhile, D. Boral Capital downgraded CorMedix’s stock rating from Buy to Hold following the company’s announcement of a public offering aimed at raising $85 million. Conversely, JMP Securities reiterated its Market Outperform rating for CorMedix, maintaining a price target of $22.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.